Medication info
Tugenonjeong 10/8 mg

Tugenonjeong 10/8 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702410 · Approved 2017.05.16 · Insurance code 642507410

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Essential hypertension: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. Heart failure: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • hyperlipidemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients who need to take both components, Candesartan cilexetil and Rosuvastatin. Candesartan cilexetil is used in patients with essential hypertension and heart failure with impaired left ventricular systolic function who have difficulty using ACE inhibitors. Rosuvastatin is used as an adjunct to diet in patients with hyperlipidemia and dyslipidemia, particularly helping to delay the progression of atherosclerosis and reduce the risk of cardiovascular disease. It also effectively reduces the risks of stroke, myocardial infarction, and arterial revascularization in high-risk patients. This medication is effectively used in the treatment of these symptoms and diseases.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Essential hypertension: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. Heart failure: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication can cause serious harm to the fetus and newborn when used during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women of childbearing potential should use appropriate contraceptive methods, and pregnant or breastfeeding women are advised not to take this medication. Patients with allergies to this medication or its components, severely impaired liver or kidney function, or a history of myopathy or hereditary angioedema should not take it. Caution is required for elderly patients, patients with hyperkalemia, and those with mildly impaired liver or kidney function, as well as patients with heart disease, and regular monitoring is recommended. This medication can cause side effects such as muscle pain or weakness, headache, dyspepsia, and itching, so patients should consult a doctor immediately if symptoms occur. Particularly, if muscle-related symptoms are severe or muscle enzyme levels are significantly increased, they should stop taking the medication and seek medical attention. Interactions may occur when taking this medication with other drugs, so patients should inform healthcare professionals of any other medications they are taking. This medication may cause dizziness or lethargy while driving or operating machinery, so caution is necessary. Keep out of reach of children and store in the original container for safety.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized itching, dermatitis, itching, joint stiffness, limb pain, photophobia, indigestion, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, weakness, increased tension, syncope, facial flushing, weight gain, facial swelling, thirst, sleep disorder, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, dysgeusia, erectile dysfunction, vascular edema, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, dizziness, hypotension, hyperkalemia, renal function impairment, increased creatinine, increased urea, increased potassium, elevated ALT, increased liver enzymes, hepatitis, jaundice, increased blood pressure, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, vertigo, positional vertigo, adrenal insufficiency, intestinal vascular edema, nausea, diarrhea, liver dysfunction, rash, urticaria, vascular edema, myalgia, weakness, elevated CK, increased serum and urinary myoglobin, rhabdomyolysis, arthralgia, myalgia, low back pain, renal function impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, weakness, joint pain, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be kept in a tightly sealed container. It is also advisable to store it at room temperature between 1 and 30 degrees Celsius, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.